These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11137408)

  • 21. Current and emerging serious Gram-positive infections.
    Menichetti F
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy for gram-positive nosocomial sepsis.
    Wood MJ
    J Chemother; 1999 Dec; 11(6):446-52. PubMed ID: 10678786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance mechanisms of gram-positive bacteria.
    Berger-Bächi B
    Int J Med Microbiol; 2002 Jun; 292(1):27-35. PubMed ID: 12139425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.
    Michel M; Gutmann L
    Lancet; 1997 Jun; 349(9069):1901-6. PubMed ID: 9217771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antimicrobial agents as therapy for resistant gram-positive cocci.
    Lentino JR; Narita M; Yu VL
    Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New antimicrobials against Gram-positive organisms].
    Montejo M
    Nefrologia; 2008; 28 Suppl 6():119-24. PubMed ID: 18957022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin intermediate and resistant Staphylococcus aureus. What the nephrologist needs to know.
    McDonald LC; Hageman JC
    Nephrol News Issues; 2004 Oct; 18(11):63-4, 66-7, 71-2 passim. PubMed ID: 15551615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
    Tiwari HK; Sen MR
    BMC Infect Dis; 2006 Oct; 6():156. PubMed ID: 17067393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Cadena J; Javeri H
    Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia.
    Roghmann MC
    Arch Intern Med; 2000 Apr; 160(7):1001-4. PubMed ID: 10761966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
    Boneca IG; Chiosis G
    Expert Opin Ther Targets; 2003 Jun; 7(3):311-28. PubMed ID: 12783569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
    Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
    J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of mecA gene and borderline oxacillin resistant Staphylococcus aureus in nosocomial acquired methicillin resistance Staphylococcus aureus infections.
    Khorvash F; Mostafavizadeh K; Mobasherizadeh S
    Pak J Biol Sci; 2008 May; 11(9):1282-5. PubMed ID: 18819540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.